XOMA (XOMAO) Stock Analysis

What XOMA does

Based in Emeryville, California, and founded in 1981, XOMA Corporation functions as a specialized biotechnology royalty aggregator, with operations spanning Europe, the United States, and the Asia Pacific. The company's core mission is to contribute to advancing human health by empowering other biotechnology firms. XOMA achieves this by purchasing the future economic interests, often in the form of royalties, associated with therapeutic candidates still in their pre-commercial development stages, which have already been licensed to pharmaceutical or biotechnology partners. Their strategic focus is primarily on early to mid-stage clinical assets, specifically those in Phase 1 and 2, that demonstrate significant potential for commercial sales once fully developed by their licensees. Currently, XOMA manages a substantial portfolio comprising approximately 70 such assets.

Key metrics

ETFs linked to XOMAO

Broad-market and Healthcare sector ETFs an investor holding XOMA is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how XOMAO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for XOMA?

XOMA trades under the ticker XOMAO on NASDAQ.

Which exchange is XOMAO listed on?

XOMAO is listed on NASDAQ.

What sector does XOMA operate in?

XOMA is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze XOMAO in a portfolio?

PortView shows XOMAO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.